Analysis of immune suppressor mechanisms in patients with HCC
$206,642ZIAFY2010CANIH
Division Of Basic Sciences - Nci
Investigators
Linked publications & trials
Paper 38205877Paper 38184304Paper 36754451Paper 35366023Paper 35331674Paper 34340996Paper 33508529Paper 33235387Paper 32060001Paper 31996388Paper 31912614Paper 29909986Paper 29427558Paper 29066575Paper 28857485Paper 27816492Paper 24201974Paper 23243621Paper 23108303Paper 23011590Paper 22615204Paper 22304731Paper 21493801Paper 21237299
Abstract
It has been shown that tumors have developed numerous ways to escape tumor specific immune responses. These mechanisms will ultimately not only enhance tumor growth, but also impair the effect of immune based therapies in cancer. Myeloid derived suppressor cells represent a recently identified cell population, which has been shown to impair tumor specific immune responses both in mice and human. We have been able to identify a human counterpart of the initially only in mice described MDSC, which is characterized by the expression of CD14 and low/no levels of HLA-DR.
View original record on NIH RePORTER →